TYRA

Tyra BiosciencesF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$33.00

Analysis reference price unavailable

Analysis 2026-10-26 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$19.00

Analysis reference price unavailable

Analysis 2026-10-26 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$9.00

Analysis reference price unavailable

Analysis 2026-10-26 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-26

AI commentary

Coverage described a sharp negative reaction to the September SURF302 data, notwithstanding TYRA's favorable interpretation of early responses. The October 23 price anchor is $20.45; the packet does not establish whether the initial reaction held or reversed on a comparable basis. No reliable post-readout target revisions, social coverage, options skew, short-interest or employee score were supplied. The negative deterministic directional prior and thin forward evidence favor monitoring rather than treating financing as clinical de-risking.

RankAlpha Sentiment Codex - 2026-10-26

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2027-01-24eventSURF302 dose and Phase 3 development decisionsHigh impact

Initial Phase 2 data supported 60 mg daily for TYRA's planned adjuvant strategy, but the 64% best-overall complete-response rate came from just 14 evaluable patients across single- and multiple-lesion groups. Subsequent dose selection and trial design must establish whether that early signal can translate into durable benefit; no decision date is confirmed. [#PR-EARNINGS-2026-09-09]

2027-03-31eventBEACH301 achondroplasia readoutHigh impact

TYRA expected initial Phase 2 safety-sentinel data from approximately 25 children, including a fifth dose level, by the end of Q1 2027. Safety and growth-velocity evidence will determine whether dabogratinib has a credible second development path. [#SEC-8K-2026-08-04]

2027-10-26catalystSURF303 low-grade UTUC developmentHigh impact

TYRA is studying dabogratinib in low-grade upper-tract urothelial carcinoma. The reported three-month complete response in the first treated patient is anecdotal; a larger dataset is needed before assigning meaningful efficacy value. [#SEC-8K-2026-08-04] [#PR-EARNINGS-2026-09-09]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-26 • Updated nightlySource: Internal modelMethodology